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Summary
Canine immune thrombocytopenia (ITP) is analogous to human ITP, with similar platelet counts
and heterogeneity in bleeding phenotype among affected individuals. With a goal of ultimately
investigating this bleeding heterogeneity, a canine model of antibody-mediated ITP was
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developed. Infusion of healthy dogs with 2F9, a murine IgG2a monoclonal antibody to the canine
platelet glycoprotein GPIIb (a common target of autoantibodies in ITP) resulted in profound, dose-
dependent thrombocytopenia. Model dogs developed variable bleeding phenotypes, e.g. petechiae
and haematuria, despite similar degrees of thrombocytopenia. 2F9 infusion was not associated
with systemic inflammation, consumptive coagulopathy, or impairment of platelet function.
Unexpectedly however, evaluation of cytokine profiles led to the identification of platelets as a
potential source of serum interleukin-8 (IL8) in dogs. This finding was confirmed in humans with
ITP, suggesting that platelet IL8 may be a previously unrecognized modulator of platelet-
neutrophil crosstalk. The utility of this model will allow future study of bleeding phenotypic
heterogeneity including the role of neutrophils and endothelial cells in ITP.
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Introduction
Immune thrombocytopenia (ITP) is a bleeding disorder in which platelet autoantibodies lead
to thrombocytopenia and, sometimes, severe bleeding (Nieswandt et al, 2000). A major
unanswered question in ITP is the variable bleeding tendency; specifically, why do some
patients have more bleeding manifestations while others with equally low platelet counts
have less? This clinical heterogeneity impairs the clinicians' ability to decide which patients
need more aggressive management (Eldor et al, 1982; Kenet et al, 1998; Psaila et al, 2011).
Further investigations are necessary to better understand, predict and correct the bleeding
phenotype in ITP.
Although much has been learned from murine models of ITP, striking differences exist
between mice and humans, including platelet counts (1 million platelets/μl in mice versus
150-400 ×109/l in humans), platelet volume (murine platelets are about half the size of
human platelets), and platelet signalling pathways (Table I) (Levin & Ebbe, 1994; Semple,
2010; Ware, 2004).
While there are currently no large animal models of ITP, dogs may be ideal for this purpose.
Dogs develop spontaneous ITP with a similar disease course, heterogeneous bleeding
phenotype, and response to treatment as adult humans with ITP (Lewis & Meyers, 1996).
Dogs are much closer in size to humans, resulting in more similar rheology (Son et al, 2010;
Suo et al, 2007) and metabolic rates (Schmidt-Nielsen & Pennycuik, 1961), and dogs and
humans have similar platelet counts and platelet volumes. Hundreds of times more blood
volume can be safely sampled from dogs than mice (Diehl et al, 2001), and non-terminal
studies are possible in dogs. Finally, platelet signalling pathways are more analogous
between dogs and humans, with canine and human platelets signalling through protease-
activated receptors (PAR)1 and PAR4, while murine platelets utilize PAR3 and 4 (James
Catalfamo, Cornell University, personal communication, November 8, 2012) (Boudreaux et
al, 2007; Kahn et al, 1999; Nakanishi-Matsui et al, 2000; Ware, 2004).
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We sought to develop a canine ITP model that would be highly translational because of the
similarities between canine and human platelets and because dogs develop spontaneous ITP
as do humans. An antibody-mediated model is desirable as an initial approach because it
recapitulates ITP without the confounding co-morbidities or treatment effects present in
clinical cases. We employed 2F9, a murine anti-platelet antibody targeting canine platelet
glycoprotein IIb (GPIIb), to model the autoantibody-induced clearance of platelets in ITP.
We selected an anti-GPIIb antibody because autoantibodies in human patients with ITP are
most commonly directed against epitopes on GPIIbIIIa, the fibrinogen receptor, and GPIb-
IX-V, the von Willebrand factor receptor (Beardsley & Ertem, 1998). Infusing antibodies
against GPIIbIIIa in murine models leads to incompletely understood acute systemic
reactions and hypothermia (Nieswandt et al, 2000; Nieswandt et al, 2003). Thus, these
murine models fail to recapitulate the naturally-occurring disease in which the predominant
clinical manifestations, if any, are mucocutaneous bleeding and fatigue (Newton et al,
2011).
The generation of platelet autoantibodies in ITP is the tip of the immunological iceberg.
Autoantibodies form in ITP as the result of a complex loss of self-tolerance, including
formation of autoreactive B and T cells, autoreactive cytotoxic T cells and decreased
regulatory T cells (Gernsheimer 2008; Olsson et al, 2003). The immunopathogenesis of ITP
has been extensively reviewed elsewhere (Semple & Provan 2012). Furthermore, in addition
to accelerated platelet destruction, ineffective platelet production is now understood to be
central in disease pathogenesis (Gernsheimer 2008; Chang et al, 1999; McMillan et al,
2004). We are beginning to recognize that ITP is probably a heterogeneous syndrome with a
final common pathway of platelet autoantibodies and platelet destruction (Arnold 2012).
Thus, our passive ITP model only recapitulates one segment of a complex disease.
Despite these limitations, ultimately, this novel large animal model should be useful to
investigate the pathophysiology of autoantibody-mediated thrombocytopenia, as well as
reasons for the differential bleeding tendency in affected humans and dogs.
Materials and Methods
Complete and detailed methods are provided in the Online Supplement. In brief, we
developed a canine ITP model by infusion of purpose-bred research dogs with a murine
monoclonal antibody, 2F9, recognizing canine GPIIb (Burstein et al, 1991; Suter et al, 2007;
Fang et al, 2011). 2F9 is a platelet-specific IgG2a antibody developed by Burstein and
colleagues by immunizing mice with canine platelets (Burstein et al, 1991). The 2F9
hybridoma was gifted to us by David Wilcox (Medical College of Wisconsin, Milwaukee,
WI), and 2F9 antibody was produced from this hybridoma by the Tissue Culture Facility,
University of North Carolina, Chapel Hill. Western blot analysis was performed to confirm
the specific reactivity of 2F9 with GPIIb by using control dog platelets and platelets from
dogs with Glanzmann thrombasthenia (GT) (Boudreaux et al, 2007).
To model the clinical disease with variable bleeding tendencies at platelet counts below 30 ×
109/l, we performed a dose-titration study in two dogs, aiming for a target platelet nadir of
5–30 × 109/l. 2F9 was administered at a starting dose of 15 ng/kg i.v. The dose was
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increased by a factor of ten every 1–2 h until the platelet count fell in the target range. Time
zero was when the platelet count first fell into the target nadir range. Subsequently, three
dogs were employed in a dose-repeatability study, receiving starting 2F9 doses of 50 μg/kg,
based on the dose-titration study results; additional doses were given as needed and were
based on their decrease in platelet count in response to the first 2F9 dose. Three dogs served
as controls. They received anti-yellow fever IgG2a, the isotype control antibody, at the
highest cumulative effective dose of 2F9 administered (167 μg/kg).
Blood was drawn at the following time points: baseline, time zero (when platelet count first
fell into the target range or 1 h after control antibody administration), 2, 4, 6, 8, 12 and 24 h,
and then every 24 hours until platelet count recovered and new bleeding stopped, whichever
came later (168-240 h; termed recovery). Blood sampling and processing details are
described in the supplementary methods.
To compare our experimental model with spontaneous canine ITP, blood samples were also
obtained from dogs with naturally-occurring ITP (n=6) or thrombocytopenia of other causes
(n=4). Signalment information for these dogs with naturally-occurring thrombocytopenia is
listed in Supplementary Table 1.
Bleeding quantification
Bleeding was assessed by one author at all time points using a bleeding scale adapted from
the human ITP bleeding score (Supplementary Table 2) (Page et al, 2007); buccal mucosal
bleeding times were performed at baseline and time zero as previously described (Brooks &
Catalfamo, 1993).
Cytokine and Chemokine Analysis
Cytokine/chemokine profiles in dogs with spontaneous and modelled ITP were analysed in
sera by a 13-plex Milliplex Map canine cytokine magnetic bead panel (Milllipore, Billerica,
MA) that was read using a Bioplex 200 (BioRad, Hercules, CA).
Canine IL8 results by multiplex assay were confirmed using a Quantikine canine IL8
enzyme-linked immunosorbent assay (ELISA) (R&D, Minneapolis, MN). Serum IL8 was
also measured in human patients with ITP. Adult ITP patients were recruited at the Platelet
Disorder Center, Weill Cornell Medical College/New York Presbyterian Hospital, NY.
Patients consented and were enrolled in this Institutional Review Board–approved study.
Serum IL8 was measured using a high sensitivity human IL8 immunoassay (R&D).
Fibrinogen and D-dimer Analysis
Coagulation analytes were measured in citrated plasma in the Comparative Coagulation
Laboratory, Animal Health Diagnostic Laboratory, Cornell University as previously
described (Stokol et al, 2000; Delgado et al, 2009).
Statistical Analysis
To test for differences in outcomes across all time points by treatment group (2F9 or control
antibody), repeated-measures generalized linear modeling (analysis of variance [ANOVA])
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was performed, where time point and variable of interest were entered into the model.
Similarly, to screen for differences in variables in dogs with spontaneous ITP, healthy dogs
and experimental dogs, a repeated-measures ANOVA was performed. The sole dog with
secondary ITP was not considered in these analyses. To control for multiple testing, a
Bonferroni correction was used (for each set of hypotheses) to determine the alpha level for
statistical significance that ensured a family-wise error rate of 0.05; a comparison was
considered to be statistically significant here if P<0.002. When differences between groups
were identified, the Wilcoxon rank sum test was used to compare pairs of different groups of
dogs (dogs with spontaneous ITP, experimental ITP and control dogs, healthy dogs). The
Wilcoxon rank sum test was also used to compare nadir platelet counts for control and 2F9-
treated dogs. Results were considered significant if P<0.05.
To identify candidate predictors of bleeding, the association between bleeding scores and
different mediators was determined by univariate association between variables using a t-test
for correlations with appropriate degrees of freedom. Bleeding scores were treated as
ordinate variables as described by Mantel-Haenszel. Again, a Bonferroni correction was
applied, with P<0.002 considered significant. A t-test for correlations was also used to
evaluate the relationship between platelet count and IL8 levels.
All calculations were performed using Stata version 10 (Statacorp LP). Graphs were drawn
with GraphPad PRISM 5.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Ex Vivo Characterization of 2F9
By Western blot analysis, we determined that 2F9 does not recognize any protein bands in
canine GT platelets, indicating that 2F9 must bind to either GPIIb or GPIIIa (Figure 1)
(Boudreaux & Catalfamo, 2001). In normal canine platelets, 2F9 reacts with a band in the
non-reduced state that is most prominent at 124 kDa, with weaker areas extending to 148
kDa and 110 kDa. This band is close to the predicted size of canine GPIIb (Abuelo et al,
2012).
Based on flow-cytometric studies, 2F9 did not lead to platelet activation (surface expression
of P-selectin or phosphatidylserine) or inhibit platelet responsiveness to thrombin
stimulation (data not shown).
In Vivo ITP Model Development
2F9 Induces a Severe, Dose-Dependent Thrombocytopenia—Within 2 h of a
median cumulative 2F9 dose of 63 μg/kg (range 50.0-166.6 μg/kg), all dogs developed
profound thrombocytopenia (11-28× 109/l) (Figure 2). Compared to the control group,
platelet nadir was significantly lower (median (range): 6 (4-11) × 109/l vs. 200 (179-209) ×
109/l; P=0.036) and change in platelet count from baseline to nadir was significantly greater
in the 2F9-treated group (median (range): 238 (179-325) × 109/l vs. 4 (0-10) × 109/l;
P=0.036). Platelet nadir was in our target range (5-30 × 109/l) and platelet count remained
less than 40 × 109/l in all 2F9-treated dogs for 24 h. Nadir platelet counts averaged 3% of
baseline. Dosing was predictable: in the dose-repeatability dogs, after an initial dose of 50
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μg/kg 2F9, the second dose needed to reach the target nadir could be accurately calculated
from the initial platelet decrease according to the following formula, where Δ platelet count
is change in platelet count:
Due to the dose-titration component of the study, dogs received up to 6 doses of 2F9 within
a period of 3 days. Dose response details are tabulated in Supplementary Table 3. Platelet
counts recovered in 5 to 10 days (median 6 days).
Dogs remained bright, alert, and responsive throughout the study. Temperature, pulse, and
respiration were unchanged during antibody administration and remained within normal
limits at all time points (not shown). Transient neutropenia was observed in two dogs
(Supplementary Figure 1).
ITP Model Dogs Demonstrate Variable Bleeding—Thrombocytopenic dogs
demonstrated a range of mild bleeding, from few cutaneous petechiae and/or ecchymoses to
transient microscopic haematuria or transient melena. Bleeding scores ranged from 0 to 4
out of a possible 16 (Supplementary Figure 2). Overall, bleeding was clinically mild and
required no supportive care. Interestingly, two dogs developed large delayed ecchymoses
(up to 8.5 × 13 cm) when their platelet counts were already recovering (at 48 - 120 h in one
dog and 120 - 192 h in the second animal). Figure 3 demonstrates one such ecchymosis and
the platelet counts at which these bruises developed. Histological examination of these
bruises following cutaneous biopsies revealed only perivascular haemorrhage with no
evidence of inflammatory infiltrate, cellular necrosis or thrombosis (data not shown).
Buccal mucosa bleeding times (BMBTs), performed as another way to quantify bleeding
tendency, were variably prolonged at time zero in 2F9-treated thrombocytopenic dogs from
4.80±2.09 times baseline compared to 2.15±0.32 times baseline in control animals.
Interestingly, the longest time-zero BMBTs were in the two dogs that later developed the
delayed ecchymoses (>15 min and 13.13 min). Thrombocytopenic dogs all had prolonged
BMBTs. When only the thrombocytopenic BMBTs were considered (platelet nadir in 2F9-
treated dogs), there was no correlation between platelet count and BMBT (correlation
coefficient -0.2108 (p>0.7336); Spearman rank correlation). However, negative conclusions
must be interpreted in light of the small sample size.
Induced ITP Model Is Not Prothrombotic—Both fibrinogen and D-dimers increased
slightly over time in both treated (n=5) and control (n=3) groups, but no difference (P=0.268
fibrinogen; P=0.457 D-dimers) was noted between experimental groups, indicating that, as
expected, thrombocytopenia was not explained by disseminated intravascular coagulation
(DIC) (Supplementary Figure 3).
Experimental ITP Cytokine/Chemokine Profile Models the Spontaneous
Canine Disease and Identifies Platelets as an Important Source of Serum IL8
—2F9 infusion generated negligible systemic inflammation, as assessed by white blood cell
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(WBC) count and serum cytokine measurement. Changes over time in TNF-α, MCP1, IL6,
IL10, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL2, CXCL10, IFN-γ,
IL7, IL15, CXCL1 orthologue, and IL18 were not significantly different between 2F9 and
αYFA treated dogs (Supplementary Figure 4). Unexpectedly, however, serum IL8 levels
tracked faithfully with platelet count, suggesting that platelets are a major source of serum
IL8 (Figure 4A-B). IL8 was significantly different between control and 2F9-treated dogs
(P=0.000); WBC counts were not different between control and treated dogs over time (data
not shown). These results were confirmed with an ELISA specific for canine IL8. Although
absolute values of serum IL8 were higher in the multiplex assay than the ELISA, the relative
IL8 decrease with platelet depletion was consistent. Although α-granules are known to
contain IL8 (Gear & Camerini, 2003), platelets have not been previously described as a
significant source of IL8 in serum. As IL8 is an important neutrophil chemokine, our finding
may illuminate a novel mechanism of platelet-neutrophil crosstalk.
In light of our unexpected IL8 findings in the dog antibody model, we investigated whether
the same pattern of decreased IL8 was present in dogs with spontaneous ITP. Ten dogs with
naturally-occurring thrombocytopenia were evaluated, including 5 with primary ITP, 1 with
secondary thrombocytopenia due to Ehrlichiosis and 4 with thrombocytopenia of other
causes (Supplementary Tables 1&4). Significantly decreased levels of serum IL8 were
found in all dogs with naturally-occurring thrombocytopenia (primary ITP, P=0.0016; other
causes of thrombocytopenia, P=0.0162) compared to healthy control dogs as shown in
Figure 4C.
No cytokine/chemokine differences were detected between dogs with spontaneous ITP and
the experimental ITP animals (repeated-measures ANOVA, Supplementary Table 4). The
cytokine and chemokine profile of dogs with spontaneous primary ITP was similar to that of
our experimental dogs at platelet nadir and at 24 h (Supplementary Table 4), suggesting that
the ITP model recapitulates the naturally-occurring disease in dogs.
Finally, to determine whether serum IL8 levels track with platelet count in humans, serum
IL8 levels were evaluated in human ITP patients with variable platelet counts (n=16). Serum
IL8 levels were significantly correlated with platelet count (Spearman rank correlation=0.52;
P=0.0410); (Figure 5). The nearly 100 times lower serum IL8 levels in humans compared to
canines was not unexpected given previous reports and probably relates to differing IL8
levels in human versus canine platelets (Su et al, 1996; Gelaleti et al, 2012; Elewa et al,
2010).
Identification of Candidate Bleeding Predictors—As a preliminary survey to
identify candidate predictors of bleeding, we examined whether any correlation existed
between the measured cytokine levels and bleeding scores. No correlations were found in
experimental dogs, which is not surprising given their relatively low bleeding scores. In
dogs with spontaneous primary ITP, IL10 levels were directly correlated with bleeding score
(R2=0.6053, P<0.022) in univariate analysis, but this was not significant with multiple
testing corrections. This relationship warrants further investigation in humans and dogs with
ITP.
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We have developed a canine model of ITP that is highly analogous to the naturally
occurring, spontaneous platelet autoantibody-mediated disease in dogs and humans. We
characterized 2F9 as an antibody that targets the GPIIb/IIIa complex, with an
immunoblotting pattern that is most consistent with GPIIb reactivity (Figure 1). These data
confirm the suggestion by Burstein et al. (1991) that 2F9 targets GPIIb. The GPIIb
specificity of 2F9 enhances its value for development of an ITP model, as the majority of
platelet autoantibodies in ITP target epitopes on the fibrinogen receptor (GPIIbIIIa) and von
Willebrand factor receptor (GPIb-IX-V) (Beardsley & Ertem, 1998). Furthermore, GPIIb is
an ideal target when examining the role of endothelial integrity in ITP bleeding phenotype
as GPIIb is located exclusively on platelets, while GPIIIa is also expressed by endothelial
cells. However, it should be noted that in ITP patients with autoantibodies against the
GPIIbIIIa complex, GPIIIa is targeted in the majority of cases (Mehta et al, 2000). We also
demonstrated that 2F9, as assessed by flow cytometry, is not an activating or inhibitory
antibody. This makes 2F9 an excellent choice to study platelet function in ITP.
Our in vivo studies demonstrated that the effects of 2F9 dosing were repeatable and the dose
could be tailored to reach a desired platelet nadir. With a starting dose of 50 μg/kg, the initial
platelet decrement could be used to calculate the additional dose necessary to reach a
clinically relevant target nadir of 5-30 × 109 platelets/l, the range at which ITP patients are
at risk for bleeding. Analogous to spontaneous ITP, experimental dogs demonstrated
variable mucocutaneous bleeding, ranging from few cutaneous petechiae and/or ecchymoses
to transient microscopic haematuria and melena (Cines et al, 2009; O'Marra, et al, 2011;
Provan et al, 2010; Psaila et al, 2011; Psaila et al, 2009; Rozanski et al, 2002). Experimental
dogs also had prolonged BMBTs, analogous to dogs with spontaneous thrombocytopenia
(Jergens et al, 1987). Bleeding in these dogs was mild, probably reflecting the short duration
of thrombocytopenia. Two dogs developed delayed ecchymoses during platelet recovery. As
suggested by transmission electron micrographs of these skin lesions (not shown), these
ecchymoses may be the result of altered endothelial integrity due to previous severe
thrombocytopenia and loss of platelet-vascular stabilizing effects (Gimbrone, et al, 1969;
Ho-Tin-Noe et al, 2011; Kitchens & Pendergast, 1986). Consistent thrombocytopathia due
to persistent 2F9-platelet binding was excluded by daily flow cytometry evaluations (data
not shown). Platelet function was not extensively pursued in this study but is a primary goal
of future studies. Lastly, plasma Factor VIII level of activity was also normal at the time of
bruising (data not shown).
Significantly, our model does not cause clinically significant signs of inflammation, such as
fever, and the cytokine profile in experimental ITP dogs matched that of dogs with
spontaneous primary ITP (Supplementary Table 4). Similarly, adult patients with ITP do not
manifest clinical signs of systemic inflammation. Adult ITP is, however, marked by a type-1
immune response with elevated T-helper cell type 1 (Th1) cytokines (IL2, IFN-γ) and
decreased Th2 cytokines (IL4 and IL5) (Panitsas et al, 2004; Semple et al, 1996). We did
not observe a Th1 cytokine profile in our experimental or clinical dogs, but our sample size
may have been too small to detect this pattern and we did not expect a passive ITP model to
demonstrate a lymphocytic autoimmune response.
LeVine et al. Page 8






















Our dog model sharply contrasts with murine models of ITP induced by antibodies against
GPIIbIIIa. In these models, mice develop acute systemic reactions, uncoordinated
movements and hypothermia through incompletely understood mechanisms involving
platelet-activating factor (Nieswandt et al, 2000; Nieswandt et al, 2003). Thus, in terms of
clinical manifestations, our canine model more accurately represents human ITP than do
these murine models. Furthermore, murine models employ a species that does not naturally
develop primary ITP, and that has inherent platelet differences from humans and dogs
(Table 1). The fact that dogs develop naturally occurring ITP and have similar platelet
physiology to humans is a major advantage of our model. What is learned from the canine
passive ITP model can be directly extrapolated to the spontaneous dog model as illustrated
by this study, and from there to the human disease.
Although canine ITP models have been previously described, they have not been well
characterized and the platelet-depleting antibodies or heterologous serum employed in these
models are no longer available (Makoto Hosono, Kinki University, personal communication,
May 12, 2009) (Hosono et al, 1995; Joshi & Jain, 1977; Tocantins & Stewart, 1939). Thus,
to our knowledge, our model represents the only available large animal ITP model.
There are several murine models that address the initial pathogenesis of ITP including the
role of regulatory T cells and autoreactive T and B cells in the development of ITP
(Nishimoto et al, 2012; Chow et al, 2010). The approaches used in these models, e.g.
radiation and transplantation of sensitized cells, could also be pursued in dogs in the future.
These models, though revolutionary in their ability to capture the early immunopathogenesis
of ITP, have inherent limitations. Nishimoto and colleagues' model of regulatory T cell
depletion is complicated by its potential to lead to multiple other concurrent autoimmune
diseases in conjunction with ITP (Nishimoto et al, 2012). Moreover, in this model, mice
were considered thrombocytopenic at a platelet count equivalent to a normal human platelet
count (Nishimoto et al, 2012).
We recognize that our model has limitations similar to any passive antibody-mediated model
of ITP in that it does not fully recapitulate the immunopathogenesis that leads to endogenous
autoantibody production, nor does it address the role of autoreactive T cells in direct platelet
destruction. Thus, it only models the humoral component of platelet destruction in ITP.
However, it does clearly capture the events that occur downstream of autoantibody
generation. As such, the model has many potential applications. It can be used to determine
the efficacy and safety of selected ITP therapeutics targeting autoantibody-mediated platelet
destruction. If the duration of thrombocytopenia is inadequate to assess treatment effects,
repeated 2F9 administration or constant rate infusions of 2F9 could be administered, as
repeated exposure to 2F9 over a 3-day period was well tolerated. An alternate strategy
would be to employ a higher initial 2F9 dose, similar to that administered to our proof-of-
concept dog (300 μg/kg), which induced absolute thrombocytopenia for 3 days (data not
shown). The model could be further developed by generating caninized 2F9, which would
allow unlimited 2F9 infusions.
As dogs in the model demonstrated variable bleeding, the dog model can also be used to test
hypotheses about differential bleeding tendency. Inflammation destabilizing the vasculature
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is one suggested mechanism of thrombocytopenic bleeding. In a murine model of
thrombocytopenia, only mice that had concurrent inflammation and thrombocytopenia
developed haemorrhage (Goerge et al, 2008). Our model could be used to assess how
bleeding phenotype differs when inflammation is induced locally or systemically in
thrombocytopenic dogs. A major strength of our model for this application is that we have
confirmed that the model itself is non-inflammatory. As previously discussed, the mild
bleeding demonstrated by the model dogs was probably due to the short duration of
thrombocytopenia. Prolonging the duration of severe thrombocytopenia with repeated 2F9
administration might be necessary to better explore thrombocytopenic bleeding
manifestations. Given that variable 2F9 doses were required to reach our target platelet
nadir, the influence of 2F9 dose on bleeding outcome could be explored in future studies.
Individual variation in response to anti-platelet antibody might explain some of the bleeding
variability in human and canine ITP patients. However, our study is not well powered to
address this.
The relationship our model demonstrated between IL8 and platelet counts is intriguing
(Figures 4-5). IL8 is a CXC chemokine that serves as a potent chemoattractant and
neutrophil activator (Emadi et al, 2005; Van Damme et al, 1990). Many cells produce IL8,
including endothelial cells, neutrophils, fibroblasts, mast cells, monocytes, macrophages and
T-lymphocytes (Emadi et al, 2005; Gesser et al, 1995; Gibbs et al, 2001; Kaplanski et al,
1994; Larsen et al, 1989; Matsushima & Oppenheim, 1989; Rodenburg et al, 1999; Strieter
et al, 1990a; Strieter et al, 1990b). Although platelets and megakaryocytes are known to
contain IL8 in their α-granules, they have not been considered a major source of soluble IL8
(Gear &Camerini, 2003; Iannacone et al, 2008; Su et al, 1996; von Hundelshuasen &
Weber, 2007). Studies have previously reported a direct correlation between serum IL8 and
platelet count in patients with hepatocellular carcinoma (Ren et al, 2003; Elewa et al, 2010).
However, the significance of this correlation was not explored, nor were these studies able
to show, as ours did, a recovery of serum IL8 with platelet count recovery. In our study,
serum IL8 was not correlated with other blood cell counts, including neutrophils (data not
shown). Thus, our data suggest that platelets are a major source of serum IL8, although the
possibility remains that other cells that require the presence of platelets to release IL8 are the
actual source of IL8. We also found that a marked decrease in serum IL8 is present in
naturally occurring canine (Figure 4C) and human (Figure 5) ITP. It is important to note that
IL8 was similarly reduced in dogs with non-destructive causes of thrombocytopenia such as
consumption (DIC) and myelodysplastic syndrome (Figure 4C, Supplementary Table 1),
suggesting that the mechanism of thrombocytopenia was not related to serum IL8 depletion.
Although the role, if any, of IL8 in ITP pathogenesis is not known and not addressed in this
study, we speculate a novel mechanism of platelet-neutrophil interaction. By recruiting
leucocytes into inflamed tissues, platelets are now seen as important players in inflammatory
disorders (Devi et al, 2010; Ho-Tin-Noe et al, 2011). Multiple mechanisms for platelet-
leucocyte recruitment have been described, however, platelet secretion of IL8 has not, to our
knowledge, been described as an important mechanism of leucocyte recruitment (Devi et al,
2010; Kameyoshi et al, 1992; Dole et al, 2005). As IL8 is a major neutrophil chemokine,
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this putative mechanism of platelet-neutrophil crosstalk warrants further investigation and
this model offers an excellent opportunity to do so (Van Damme et al, 1990).
Two model dogs became neutropenic (Supplementary Figure 1), one only transiently. We
confirmed that the dog with prolonged neutropenia was not septic. We were unable to detect
2F9 or canine IgG, IgM or complement binding of the dog's neutrophils (data not shown).
The neutropenia resolved following administration of GM-CSF (Neupogen, Amgen,
Thousand Oaks, CA). 2F9 does weakly bind neutrophils in the presence, but not in the
absence, of platelets (data not shown). This is believed to be due to a nonspecific interaction
of the Fc portion of platelet-bound 2F9 with neutrophil Fc receptors. The neutropenia may
have been the result of this non-specific 2F9 neutrophil binding leading to neutrophil
destruction via off-target complement fixation or phagocytosis of immune-complex
opsonized neutrophils (Shashidharamurthy et al, 2008; Hart et al, 2004). The very nature of
the mechanism of platelet depletion (platelet-antibody complexes) means neutrophils will be
activated via their Fc receptor to some degree, probably enough to marginate and, with
complement fixation, perhaps enough to deplete them. The neutropenia may have also been
the result of generalized stimulation of the reticuloendothelial system secondary to 2F9
administration. Notably however, no relationship was identified between serum IL8 levels
and neutrophil counts.
In dogs with primary ITP, the bleeding score directly correlated with serum IL10 levels. In
some studies, but not others, decreased serum IL10 levels have been observed in human ITP
with increasing levels during platelet recovery (Andersson et al, 2000; Lazarus et al, 2000;
Panitsas et al, 2004). Our results warrant further investigation of the relationship between
IL10 and bleeding tendency in both canine and human ITP.
An acknowledged limitation of our study is the small sample size. Differences between
control and 2F9-treated dogs could have been missed due to limited power, some candidate
bleeding predictors in clinical patients might have been overlooked and effect size estimates
could be inaccurate. The bleeding score we used has not been validated in dogs, which may
be a study limitation, but the scoring in model dogs was performed entirely by one author so
as to avoid inter-rater variability and the bleeding score well-described the bleeding seen in
the dogs.
In summary, we have developed a unique large animal model of ITP. This model is highly
translational and representative of the naturally occurring disease in canines and humans,
especially in terms of bleeding heterogeneity. Importantly, in this pilot study we have
discovered that IL8 may play a role in mediating platelet-neutrophil interactions in canine
and human ITP patients.
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Figure 1. Antigenic specificity of 2F9
Resting platelets from normal and Glanzmann thrombasthenia (GT) dogs were lysed and 40,
20 and 10 μg were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis under non-reducing (Ox) and reducing (Red) conditions and then transferred
onto a polyvinylidene difluoride membrane which was probed with 2F9 and detected with a
goat anti-murine horseradish peroxidease antibody and enhanced chemiluminescence
substrate. Note that no bands are observed in the GT platelet lanes indicating that 2F9 binds
either GPIIb or GPIIIa. The prominent band at 124 kDa under non-reducing conditions (and
broad band ranging from 110 to 145 kDa is most consistent with 2F9 binding GPIIb. The
faint 108-kDa band under reducing conditions probably represents a small amount of GPIIb
adhered to GPIIIa despite the presence of EDTA in the reaction conditions. If 2F9
recognized GPIIIa, a band should be present at 100 kDa under both non-reducing and
reducing conditions (Boudreaux & Catalfamo, 2001).
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Figure 2. 2F9 induces a profound thrombocytopenia in vivo
Dogs received a median cumulative dose of 63 μg/kg 2F9 intravenously. Platelet counts
were determined at the indicated times. Time zero occurred when platelet count first fell
within the target platelet nadir (5-30 × 109/l), a maximum of 2 h after the last 2F9 dose, or
was defined as 1 h after control antibody administration. Injection of the isotype control
antibody (αYFA) had no significant effect on the platelet count. Results are shown as
median and range for 5 2F9-treated dogs and 3 control dogs.
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Figure 3. Delayed ecchymosis formation during platelet count recovery
A. The photograph demonstrates a large abdominal and preputial ecchymosis (8.5 cm × 13
cm at its largest) in one 2F9-treated dog that began to form when platelet count had started
to recover and continued to expand when the platelet count had exceeded baseline count. B.
Red squares on the graph of platelet count over time demonstrate the period of active
bleeding in this dog and in the second dog that developed a delayed ecchymosis (C).
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Figure 4. Serum IL8 tracks with platelet count
Serum IL8 (median, range) as measured by the Milliplex assay in 2F9-treated (A; n=5) and
isotype control (αYFA)-treated dogs (B; n=3) compared to platelet count. C. Serum IL8
levels in dogs with naturally-occurring thrombocytopenia are decreased compared to healthy
control dogs. **P=0.0016 healthy dogs (n=8) compared to primary ITP (n=5); *P=0.0162
healthy compared to thrombocytopenia other (n=4); #P=0.0357 experimental ITP at time 0
(n=5) compared to control at time 0 (n=3) and experimental at 24 h (n=5) compared to
control at 24 h (n=3). Time zero is when platelet count first fell to target nadir of 5-30 × 109
platelets/l or 1 h after isotype control administration. Horizontal lines denote median values.
Secondary ITP (n=1) was not considered in statistical analysis. Healthy dogs were not
compared with control or experimental dogs because healthy dogs were these same dogs at
baseline; instead control and experimental were compared to each other at matching time
points.
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Figure 5. Serum IL8 is directly related to platelet count in human ITP patients
Serum IL8 in human ITP patients (n = 16) measured over up to three serial visits is
correlated with platelet count (r =0.52, p =0.0410).
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Table I
Comparison of murine, canine and human platelets and canine and murine ITP model
systems
Humans Mice Dogs
Spontaneous ITP? Yes No (Semple, 2010) Yes (Lewis & Meyers, 1996)
Platelet counts 150-400 × 109/l 1 million/μl (Ware, 2004) 190-468 × 109/l
Platelet volumes 7.5-10 fl 4.7 ± 0.3 fl(Ware, 2004) 7.9-13.8 fl
Platelet protease activated-
receptors (PAR)
PAR 1 and 4 (Ware,
2004)
PAR 3 and 4 (Ware, 2004) PAR 1 and 4 (Boudreaux et al,
2007)
Blood volume that can be
safely sampled
N/A 0.2 ml (Diehl et al, 2001) (25 g
mouse)





Result of ITP models utilizing








(Nieswandt et al, 2000)
Variable bleeding, no systemic signs
other than those relating to
haemorrhage (Lewis & Meyers,
1996; O'Marra et al, 2011)
ITP, immune thrombocytopenia; GPIIbIIIa, glycoprotein IIbIIIa complex; N/A, not applicable.
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